Biomarkers /
LMO1
Overview
LIM domain only 1 (rhombotin 1) (LMO1) is a gene that encodes a protein that functions as a transcriptional regulator. The protein may also be important for protein interaction and the binding to specific DNA-binding transcription factors. Fusions, missense mutations, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
LMO1 is altered in 0.40% of all cancers with lung adenocarcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in LMO1 are LMO1 Loss (0.05%), LMO1 Amplification (0.03%), LMO1 D8N (0.04%), LMO1 E46K (0.02%), and LMO1 E99K (0.02%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.